Discovery of Novel Inhibitors of Human

Introduction
Glucocorticoid hormones play essential roles in various vital physiological processes, including regulation of carbohydrate, lipid and bone metabolism, modulation of inflammatory responses and stress. It has been indicated that excessive glucocorticoid action in many aspects is associated with insulin and leptin resistance, leading to the development of obesity, type 2 diabetes and metabolic syndrome (Oppermann, 2006) . Glucocorticoid actions depend on both the binding to glucocorticoid receptors (GRs) and the pre-receptor metabolism of the ligand cortisol and its precursor cortisone. It is well known that the pre-receptor metabolism process is mediated by 11β-HSDs, which are microsomal enzymes from the short-chain dehydrogenases/reductases superfamily. Currently, two different 11β-HSD isozymes (11β-HSD1 and 11β-HSD2) have been reported in humans (Tomlinson et al., 2004) . The 11β-HSD1 isoform, highly expressed in liver and adipose tissue, converts cortisone to the active glucocorticoid cortisol, therefore locally amplifying the glucocorticoid action in specific tissues (Fig. 1) . Clinical data suggest that inhibition of 11β-HSD1 with a non-selective inhibitor increases hepatic insulin sensitivity along with decreased glucose production (Walker et al., 1995) . It is also shown that the modulation of 11β-HSD1 activity with selective inhibitors has beneficial effects on various conditions including insulin resistance, dyslipidemia and obesity (Hermanowski-Vosatka et al., 2005) . Recently, the positive proof-of-concept results from a 28-day phase IIa clinical trial with the potent 11β-HSD1 inhibitor INCB013739 were reported by Incyte. It is indicated that treatment of type 2 diabetes mellitus patients with INCB013739 for 28 days significantly improved hepatic and peripheral insulin sensitivity and reduced fasting plasma glucose, plasma low density lipoprotein-and totalcholesterol levels (Hawkins et al, 2008) . Therefore, inhibition of tissue-specific glucocorticoid action by regulating 11β-HSD1 constitutes a promising treatment for metabolic and cardiovascular diseases (Hughes et al, 2008; Su et al., 2008) .
(Insert Figure 1)
To discover new inhibitors of 11β-HSD1 an ongoing project in our group involves the structure based drug design of novel compounds and evaluation of their inhibitory activity against human 11β-HSD1. Our previous studies indicated that some aryl sulphonamide and aryl carboxamide derivative possess moderate inhibitory activity on purified human 11β-HSD1.
Compounds 1 and 2 (Fig. 2) exhibited inhibition of human hepatic microsomal 11β-HSD1 with IC 50 values in the low micromolar range Vicker et al 2007) . It is important to have an array of structural types of 11β-HSD1 inhibitors as the physicochemical properties of the compounds will determine tissue distribution, HPA effects, and ultimately clinical utility. Here we report the discovery and the structure-activity relationships of some adamantyl carboxamide compounds as novel, potent and selective inhibitors of 11β-HSD1 in a HEK-293 cell line.
(Insert Figure 2) 2. Methods
Synthesis of target compounds (3-14)
Compounds 3-14 were synthesized from 1-adamantyl carbonyl chloride or 1-adamantyl acetic acid through an amide coupling reaction with various amines under standard conditions General method A: To a solution of 1-adamantyl carbonyl chloride (0.26 mmol) in dichloromethane (DCM, 5 mL) was added triethylamine (0.1 mL), followed by the corresponding amine (0.25 mmol). The reaction mixture was stirred at ambient temperature under nitrogen overnight. Polymer supported trisamine (4.1 mmol/g, 100 mg) was added; the mixture was stirred at room temperature for 2 h, filtered and concentrated in vacuo to give the crude product.
Purification by flash chromatography gave the adamantyl carboxamide.
General method B: To a solution of the 1-adamantane acetic acid (0.5 mmol) in DCM (8 mL)
were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI, 0.6 mmol), 4-(dimethylamino) pyridine (DMAP, 10 mg) and triethylamine (0.1 mL) at room temperature. After stirring for 0.5 h, the corresponding amine (0.5 mmol) was added to the reaction mixture. After 12 h the mixture was partitioned between DCM and brine and the organic layer was washed with brine, dried over MgSO 4 and concentrated in vacuo. The crude product was purified with flash chromatography to give the adamantyl acetamide. 
N-(Furan-2-ylmethyl)-N-methyladamantane-1-carboxamide (12).
The compound was prepared using general method A to give a white solid in 95% yield. mp 53.5-54. 
11β-HSD1 Scintillation Proximity Assay (SPA) Protocol: Human Cell Based Assay
Untransfected HEK-293 cells lack endogenous 11β-HSD1 activity and this cell line has been shown to be a suitable system for evaluating 11β-HSD1 activity after being transfected with the plasmid for expression of 11β-HSD1 or 11β-HSD2 (Schweizer et al., 2003) . The highthroughput cell-based assays were conducted on the human 11β-HSD1 transfected HEK-293 cell line with an SPA . The activity of 11β-HSD1 is measured in whole HEK-293 cells stably transfected with the HSD11B1 gene using modified literature protocols (Schweizer et al., 2003) . Cells are incubated in 96-well microplates in the presence of tritiated substrate.
Enzyme activity is determined by measuring the amount of tritiated product by SPA. Assay plates contain internal high and low controls to allow calculation of percentage inhibition. Each well of a 96-well culture plate is seeded with HEK293/HSD11B1 cells in 100 µL medium. When the cells are 80% confluent the medium is removed from each well. Then 100 µL fresh, serum-free medium containing 3 H-cortisone and test compound in 1% DMSO is added to each well, including control wells. High control wells do not contain compound, while low controls do not contain cells. The plate is incubated at 37 ºC for the required time period, after which, 50 µL of media is removed from each well and transferred to a microplate containing 100 µL of a preincubated mixture of anti-cortisol antibody and SPA bead (Fig.3) . The mixture is incubated with gentle shaking until equilibrium is reached, before transferring to a scintillation counter to establish the enzyme activity in each sample.
(Insert Figure 3) 
Molecular Modelling
The crystal structure of one subunit of human 11β-HSD1 (IXU9) from the Protein Data Bank was used in docking studies with the cofactor NADP + present (Hosfield et al., 2005; Berman et al., 2000) . The docking studies of compound 8 were performed with GOLD, version 3.1.1. Fifteen docks were performed and the GOLDscore fitness function was used to rank the docked conformations. The top three highest ranked docks were virtually identical with the top scored dock. A similar study was also performed with the substrate; the docked conformations are (Insert Figure 4a and 4b) 
Results and Discussion
Our previous studies indicated that some aryl sulphonamide and aryl carboxamide derivatives possess moderate inhibitory activity on purified human 11β-HSD1. Compounds 1 and low micromolar range Vicker et al 2007) . However, these compounds showed only < 50% inhibition at 10 μM concentration when tested in HEK-293 cells transfected with human 11β-HSD1. The highly hydrophobic adamantyl carboxamide moiety was used to replace the aryl carboxamide or sulphonamide group in these molecules which led to a slightly increased (Insert Table 1 )
Conclusions
Here we report the discovery of adamantyl carboxamide derivatives as novel potent selective 
